Monday June 24
VENUE: Runeberg hall (University main building)
The global financial crisis has accelerated trends across the developed world towards rationing in cancer care. Stories about patients being denied access to expensive treatments or investigations are becoming increasingly common, and many patients now fear being abandoned as “a hopeless case” as doctors and hospitals are forced to keep to tight budgets. However, research shows that decisions about what cancer services to offer and how are often taken by the wrong people, in the wrong way for the wrong reasons, leading to a huge waste of resources. This workshop will explore the techniques and sources journalists can use to investigate how effectively cancer services are delivered in their own health systems.
European School of Oncology
Kathy Redmond (Switzerland), editor of Cancer World Magazine.
Matti Aapro (Switzerland), dean, Multidisciplinary Oncology Institute
“What is quality cancer care”
Richard Sullivan (UK), director of King’s Health Partners Institute of Cancer Policy and Global Health
“Is quality cancer care affordable?”
Dr. Matti Aapro, dean of the Multidisciplinary Oncology Institute, Genolier, Switzerland, previously chaired the Medical and Radiation Department, European Institute of Oncology, Milano. He is Executive Board member of the International Society for Geriatric Oncology (SIOG) and European School of Oncology (ESO). He was a Board member of EORTC and ESMO. He is Past-president of the Multinational Association for Supportive Care in Cancer (MASCC), as well as on its Board of Directors for 2012-2014. He is member of the ESMO and EMCC meeting scientific committees. He is Editor-in-Chief of Critical Reviews in Oncology/Hematology, Associate Editor for Annals of Oncology and the geriatric section of the Oncologist and founding member of the Journal of Geriatric Oncology (JGO). His major interests are new drug development, breast cancer, supportive care, and cancer in the elderly. Dr. Aapro has received the 2012 ASCO B.J. Kennedy prize.
Richard Sullivan is Professor of Cancer Policy & Global Health at Kings College London and Director of the new Kings Institute of Cancer Policy. As a member of the Integrated Cancer Centre executive he leads external affairs and is also Visiting Professor (Faculty of Medicine) at Universidad Catolica, Santiago de Chile, as well as a senior fellow at the International Prevention Research Institute, Lyon. Richard also sits on the boards for Kings Centre for Global Health and the Marjan Centre for Conflict & Conservation.
Richard qualified in medicine at St. Marys Hospital, London. Following training in surgery (uro-oncology) he undertook a PhD and post-doctoral research in cell signalling at University College London. He then worked in a senior role in the pharmaceutical industry before spending nearly a decade with one of the worlds biggest NGO funders of cancer R&D Cancer Research UK as their clinical director. There he led on a number of major strategies including developing and launching the UK’s Experimental Cancer Medicine Centres and the development of the European Cancer Centres initiative. In 2008 Richard moved back into research at the London School of Economics were he studied complex healthcare systems within the health, society and population programme having previously worked in conflict and post conflict public health settings in the Balkans, Africa and most recently Middle East.
He serves on a wide variety of advisory boards, including Charite Comprehensive Cancer Centre Berlin, Irish Clinical Oncology Group, Pfizer Policy Advisory Board, et al. He is past UK Director of the Council for Emerging National Security Affairs (CENSA) a Washington-based national security think-tank where he specialised in bioweapon counter-proliferation and the security implications of global health.
Richard’s research programmes extend from the public policy of global cancer, to the development of public health systems in high-risk conflict areas focusing on DR Congo, Afghanistan & Libya. He also has a strong research interest in the development of novel therapeutics derived from the natural world, particularly medicinal mushrooms.
In cancer public policy he recently led the first major Lancet Oncology Commission that examined the affordability of cancer in high-income countries and the major review of global childhood cancer care and research. Other current cancer onco policy programmes include quantifying the economic burden of cancer in EU-27; new policies for tackling global childhood cancer burden; defining R&D excellence for the new European comprehensive cancer centre accreditation program; social media platforms for cancer community; and developing cancer R&D systems in a emerging economies, e.g. Chile, India.